Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024

Kura Oncology, Inc.

2022-Q2 EPS reported -$1.01

Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.
Cash, cash equivalents and investments total $450.3M as of June 30, 2022, providing runway through 2024.
Recommended Phase 2 dose for ziftomenib identified, pending FDA review; additional 18 patients enrolled in KOMET-001 trial.
Preliminary activity observed in KURRENT-HN trial of tipifarnib + alpelisib; first patient dosed in HRAS overexpression cohort.
KURRENT-LUNG trial of tipifarnib + osimertinib to initiate in Q3; IND for KO-2806 expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.